Genentech and DualityBio Forge $1B+ Partnership to Accelerate Novel ADC Payloads, Combat Resistance

September 6, 2026

Fierce Biotech USA

Overview

Roche’s Genentech has announced a significant collaboration with DualityBio, a deal potentially exceeding $1 billion, aimed at developing next-generation Antibody-Drug Conjugates (ADCs). This partnership will leverage DualityBio’s proprietary Dupac platform to engineer novel payloads capable of overcoming resistance in tumors that no longer respond to existing topoisomerase-based ADCs. By addressing this critical unmet need in refractory cancer treatment, the collaboration seeks to provide new therapeutic options for patients whose disease progresses after current ADC therapies.

In Depth

Background

ADCs have revolutionized cancer therapy as innovative therapeutic modalities, combining highly specific antibodies with potent cytotoxic drugs to selectively deliver agents to cancer cells. However, the emergence of treatment resistance remains a major challenge impeding the long-term success of ADC therapies. Resistance to topoisomerase inhibitor payloads, in particular, represents a significant unmet medical need for many patients. Major pharmaceutical players like Genentech proactively engaging with emerging companies like DualityBio to tackle this issue provides a strong incentive to accelerate ADC development across the industry and foster new breakthroughs.

Key Findings

Fierce Biotech reports that Genentech, a subsidiary of Roche, has forged a substantial partnership with DualityBio, a Chinese biotechnology company, involving potential milestone payments exceeding $1 billion. This collaboration will focus on developing next-generation antibody-drug conjugates (ADCs) for cancer patients whose disease progresses after existing ADC therapies. Specifically, the alliance aims to leverage DualityBio’s proprietary Dupac platform to develop novel payloads that maintain efficacy even in tumors demonstrating resistance to current topoisomerase-based ADCs. This strategic investment is positioned as a critical move to address pressing unmet needs in refractory cancer treatment.

Technical/Clinical Details

Many current ADCs utilize payloads (the drug component) that inhibit topoisomerase, an enzyme crucial for DNA function. However, cancer cells frequently develop resistance to these payloads, leading to treatment failure. DualityBio’s Dupac platform is believed to offer innovative linker technologies and payloads with novel mechanisms of action that can overcome resistance to existing payloads. ADC candidates developed under this partnership will undergo preclinical evaluation before DualityBio files an Investigational New Drug (IND) application. Following this, Genentech will assume responsibility for development from Phase 1a clinical trials onwards and global commercialization, leveraging its extensive expertise and resources.

Strategic Significance & Outlook

This strategic partnership between Genentech and DualityBio has the potential to significantly advance research and development efforts aimed at overcoming ADC resistance. Clinical trial data for novel ADC candidates developed through this collaboration are eagerly awaited. If ADCs capable of overcoming topoisomerase resistance become a reality, they would offer a groundbreaking treatment option for patients with advanced cancers currently facing limited choices, dramatically improving their survival rates and quality of life. This success could also encourage similar strategic investments from other pharmaceutical companies, further accelerating the evolution of ADC technology and expanding the therapeutic landscape.

Source: https://www.fiercebiotech.com/biotech/genentech-doubles-down-adc-resistant-cancers-1b-dualitybio-pact

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.